Glaukos Corporation (GKOS)
USD 145.14
(-0.83%)
USD 145.14
(-0.83%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 314.71 Million USD | 11.26% |
| 2022 | 282.86 Million USD | -3.79% |
| 2021 | 294.01 Million USD | 30.7% |
| 2020 | 224.95 Million USD | -5.07% |
| 2019 | 236.98 Million USD | 30.73% |
| 2018 | 181.27 Million USD | 13.83% |
| 2017 | 159.25 Million USD | 39.21% |
| 2016 | 114.39 Million USD | 59.55% |
| 2015 | 71.7 Million USD | 57.28% |
| 2014 | 45.58 Million USD | 117.64% |
| 2013 | 20.94 Million USD | 762.33% |
| 2012 | 2.42 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 85.62 Million USD | 3.95% |
| 2024 Q2 | 95.69 Million USD | 11.76% |
| 2024 Q3 | 96.67 Million USD | 1.02% |
| 2023 Q3 | 78.04 Million USD | -2.92% |
| 2023 Q2 | 80.39 Million USD | 8.8% |
| 2023 FY | 314.71 Million USD | 11.26% |
| 2023 Q4 | 82.36 Million USD | 5.53% |
| 2023 Q1 | 73.89 Million USD | 3.75% |
| 2022 Q3 | 71.26 Million USD | -1.95% |
| 2022 Q4 | 71.22 Million USD | -0.06% |
| 2022 FY | 282.86 Million USD | -3.79% |
| 2022 Q1 | 67.68 Million USD | -7.59% |
| 2022 Q2 | 72.68 Million USD | 7.39% |
| 2021 Q2 | 78.09 Million USD | 14.9% |
| 2021 Q4 | 73.24 Million USD | -1.97% |
| 2021 Q3 | 74.71 Million USD | -4.33% |
| 2021 FY | 294.01 Million USD | 30.7% |
| 2021 Q1 | 67.96 Million USD | -7.19% |
| 2020 Q1 | 55.33 Million USD | -15.97% |
| 2020 Q2 | 31.55 Million USD | -42.97% |
| 2020 Q3 | 64.83 Million USD | 105.43% |
| 2020 Q4 | 73.23 Million USD | 12.96% |
| 2020 FY | 224.95 Million USD | -5.07% |
| 2019 Q4 | 65.84 Million USD | 12.55% |
| 2019 FY | 236.98 Million USD | 30.73% |
| 2019 Q3 | 58.5 Million USD | -0.16% |
| 2019 Q2 | 58.6 Million USD | 8.47% |
| 2019 Q1 | 54.02 Million USD | -0.09% |
| 2018 Q4 | 54.07 Million USD | 23.16% |
| 2018 FY | 181.27 Million USD | 13.83% |
| 2018 Q2 | 43.16 Million USD | 7.54% |
| 2018 Q1 | 40.13 Million USD | -3.64% |
| 2018 Q3 | 43.9 Million USD | 1.73% |
| 2017 Q4 | 41.65 Million USD | 3.06% |
| 2017 FY | 159.25 Million USD | 39.21% |
| 2017 Q1 | 35.9 Million USD | 8.24% |
| 2017 Q2 | 41.28 Million USD | 14.98% |
| 2017 Q3 | 40.41 Million USD | -2.11% |
| 2016 FY | 114.39 Million USD | 59.55% |
| 2016 Q2 | 28.55 Million USD | 23.66% |
| 2016 Q3 | 29.57 Million USD | 3.58% |
| 2016 Q1 | 23.09 Million USD | 13.89% |
| 2016 Q4 | 33.17 Million USD | 12.15% |
| 2015 FY | 71.7 Million USD | 57.28% |
| 2015 Q4 | 20.27 Million USD | 6.69% |
| 2015 Q3 | 19 Million USD | 7.04% |
| 2015 Q2 | 17.75 Million USD | 21.06% |
| 2015 Q1 | 14.66 Million USD | 3.92% |
| 2014 Q2 | 11.09 Million USD | 34.55% |
| 2014 Q3 | 12.12 Million USD | 9.25% |
| 2014 Q1 | 8.24 Million USD | 25.3% |
| 2014 Q4 | 14.11 Million USD | 16.39% |
| 2014 FY | 45.58 Million USD | 117.64% |
| 2013 Q3 | 6.58 Million USD | 35.35% |
| 2013 Q1 | 2.91 Million USD | 0.0% |
| 2013 Q2 | 4.86 Million USD | 66.86% |
| 2013 Q4 | 6.58 Million USD | 0.0% |
| 2013 FY | 20.94 Million USD | 762.33% |
| 2012 FY | 2.42 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott Laboratories | 40.1 Billion USD | 99.215% |
| Allurion Technologies Inc. | 53.46 Million USD | -488.608% |
| Artivion, Inc. | 354 Million USD | 11.1% |
| Avanos Medical, Inc. | 673.3 Million USD | 53.258% |
| Butterfly Network, Inc. | 65.9 Million USD | -377.558% |
| Butterfly Network, Inc. | 65.9 Million USD | -377.558% |
| Bio-Rad Laboratories, Inc. | 2.67 Billion USD | 88.219% |
| Boston Scientific Corporation | 14.24 Billion USD | 97.79% |
| Perspective Therapeutics, Inc. | 7.1 Million USD | -4330.053% |
| CONMED Corporation | 1.24 Billion USD | 74.64% |
| Edwards Lifesciences Corporation | 6 Billion USD | 94.759% |
| Paragon 28, Inc. | 216.38 Million USD | -45.438% |
| Globus Medical, Inc. | 1.56 Billion USD | 79.935% |
| Inspire Medical Systems, Inc. | 624.79 Million USD | 49.63% |
| Integer Holdings Corporation | 1.59 Billion USD | 80.29% |
| Medtronic plc | 32.36 Billion USD | 99.028% |
| Nevro Corp. | 425.17 Million USD | 25.981% |
| Owlet, Inc. | 54.01 Million USD | -482.69% |
| Penumbra, Inc. | 1.05 Billion USD | 70.269% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 5.54 Billion USD | 94.329% |
| Sonendo, Inc. | 43.86 Million USD | -617.454% |
| STERIS plc | 5.13 Billion USD | 93.876% |
| Stryker Corporation | 20.49 Billion USD | 98.465% |
| Vapotherm, Inc. | 68.66 Million USD | -358.301% |
| Zimmer Biomet Holdings, Inc. | 7.39 Billion USD | 95.744% |